HUTCHMED (CHINA) LIMIT

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

08 ноя 2023 18:11:18 Источник Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

16 окт 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

29 сен 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

12 сен 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

11 сен 2023 19:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

28 авг 2023 19:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

20 авг 2023 19:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

31 июл 2023 06:41:53 Источник Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

19 июл 2023 19:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Changes to Board of Directors and Technical Committee 

13 июл 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

09 июл 2023 19:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Half-Year Financial Results

26 июн 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

15 июн 2023 19:30:00 Источник Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

15 июн 2023 09:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

09 июн 2023 04:30:00 Источник Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

25 май 2023 18:00:54 Источник Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

25 май 2023 17:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Board of Directors and Board Committee Membership

12 май 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

10 май 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

17 апр 2023 19:00:00 Источник Nasdaq GlobeNewswire